Temozolomide and sorafenib as programmed cell death inducers of human glioma cells

Pharmacological Reports

Volumn 69, Issue 4, 2017, Pages 779-787

  Jakubowicz Gil, Joanna ^a   Bądziul, Dorota ^d   Langner, Ewa ^b   Wertel, Iwona ^c   Zając, Adrian ^a   Rzeski, Wojciech ^a,b  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

ER stress; Gliomas; Heat shock proteins; Programmed cell death; Sorafenib; Temozolomide

Indexed keywords

BECLIN 1; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 72; LIGHT CHAIN 3 PROTEIN; MYOSIN LIGHT CHAIN; SEQUESTOSOME 1; SMALL INTERFERING RNA; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DACARBAZINE; NICOTINAMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA CELL LINE; GLIOBLASTOMA MULTIFORME CELL LINE; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IN VITRO STUDY; INCUBATION TIME; MICROSCOPY; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ASTROCYTOMA; DRUG EFFECT; GENE EXPRESSION REGULATION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; CELL LINE, TUMOR; DACARBAZINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RNA INTERFERENCE;

EID: 85019994306     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2017.03.008     Document Type: Article

References (19)

1. Omuro, A.M., Faivre, S., Raymond, E., Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6 (2007), 1909–1919.
2. Lo, H.W., Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 10 (2010), 840–848.
3. Sieglin, M.D., Raskett, C.M., Gilbert, C.A., Ross, A.H., Altieri, D.C., Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 478 (2010), 165–170.
4. Nabors, L.B., Supko, J.G., Rosenfeld, M., Chamberlain, M., Phuphanich, S., Batchelor, T., et al. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neur Oncol 13 (2011), 1324–1330.
5. Kanzawa, T., Germano, I.M., Komata, T., Kondo, Y., Kondo, S., Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11 (2004), 448–457.
6. Roos, W.P., Batista, L.F., Naumann, S.C., Wick, W., Weller, M., Menck, C.F., et al. Apoptosis in malignant gliomas cells triggered by temozolomide-induced DNA lesion O6-methyguanine. Oncogene 26 (2007), 186–197.
7. Jakubowicz-Gil, J., Langner, E., Rzeski, W., Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. Pharmacol Rep 63 (2011), 403–416.
8. Jakubowicz-Gil, J., Langner, E., Badziul, D., Wertel, I., Rzeski, W., Apoptosis induction in human glioblastoma multiforme T98G cells upon Temozolomide and quercetin treatment. Tumor Biol 34 (2013), 2367–2378.
9. Jakubowicz-Gil, J., Langner, E., Bądziul, D., Wertel, I., Rzeski, W., Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. Neurotox Res 26 (2014), 64–77.
10. Bradford, M.M., A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976), 248–254.
11. Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970), 680–685.
12. Hainsworth, J.D., Ervin, T., Friedman, E., Priego, V., Murphy, P.B., Clark, B.L., et al. Concurrent radiotherapy and Temozolomide followed by Temozolomide and sorafenib in first-line treatment of patients with glioblastoma multiforme. Cancer 116 (2010), 3663–3669.
13. Zhustovich, F., Landi, L., Lombardi, G., Porta, C., Galli, L., Fontana, A., et al. Sorafenib plus daily low-dose Temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 33 (2013), 3487–3494.
14. Abraham, M.C., Shaham, S., Death without caspases, caspases without death. Trends Cell Biol 14 (2004), 184–193.
15. Würstle, M.L., Laussmann, M.A., Rehm, M., The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res 318 (2012), 1213–1220.
16. Bröker, L.E., Kruyt, F.A., Giaccone, G., Cell death independent of caspases: a review. Clin Cancer Res 11 (2005), 3155–3162.
17. Gupta, S., Deepti, A., Deegan, S., Lisbona, F., Hetz, C., Samali, A., Hsp72 protects cells from ER stress-induced apoptosis via enhancement of ire1α-xbp1 signaling through a physical interaction. PLoS Biol, 8, 2010, e1000410.
18. Stetler, R.A., Gan, Y., Zhang, W., Liou, A.K., Gao, Y., Cao, G., et al. Heat shock proteins: cellular and molecular mechanisms in the CNS. Prog Neurobiol 92 (2010), 184–211.
19. Graner, M.W., Cumming, R.I., Binger, D.D., The heat shock response and chaperone/heat shock proteins in brain tumors: surface expression, release and possible immune consequences. J Neurosci 27 (2007), 11214–11227.